Analysts think ZNTL stock price could increase by 277%
Sep 13, 2025, 11:25 AM
12.08%
What does ZNTL do
Zentalis Pharmaceuticals, a San Diego-based clinical-stage biopharmaceutical company, develops novel small molecule therapeutics for cancer, including WEE1 inhibitor azenosertib and BCL-2 inhibitor ZN-d5. The company went public on April 3, 2020, and employs 168 people.
10 analysts think ZNTL stock price will increase by 276.51%. The current median analyst target is $5.61 compared to a current stock price of $1.49. The lowest analysts target is $2.52 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.